63.15 USD
↗ 3.47 (5.81%)AT CLOSE (11:59 AM EDT)
AnaptysBio, Inc. Common Stock
ANABNASDAQ • USD
62.49
↘ 0.66 (1.05%)
POST MARKET (AS OF 07:12 PM EDT)
Post Market
AS OF 07:12 PM EDT
62.49
↘ 0.66 (1.05%)
Market: CLOSED
AnaptysBio, Inc. Common Stock (ANAB) trades at $63.15 per share. ANAB shows a split signal: technical indicators suggest "Strong Buy" while underlying fundamentals indicate "Sell". Notable factors include a weak Piotroski F-Score of 1/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Jun 26, 2026.
Open?$59.61
High?$63.28
Low?$58.62
Prev. Close?$59.68
Volume?1.4M
Avg. Volume?549.8K
VWAP?$61.72
Rel. Volume?2.48x
Bid / Ask
Bid?$55.46 × 100
Ask?$67.00 × 100
Spread?$11.54
Midpoint?$61.23
Valuation & Ratios
Market Cap?1.8B
Shares Out?29.1M
Float?17.1M
Float %?61.6%
P/E Ratio?N/A
P/B Ratio?144.17
EPS?-$0.92
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Employees
104
Market Cap
1.7B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2017-01-26
Address
10770 WATERIDGE CIRCLE, SUITE 210
SAN DIEGO, CA 92121
Phone: 858-362-6295
SAN DIEGO, CA 92121
Phone: 858-362-6295
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?38
Momentum?50
Short Sent.?16
Piotroski F-Score?1/9Weak
Altman Z-Score?2.09Grey
Confidence?65%Moderate
Short InterestSqueeze Risk
Short % of Float?27.17%Squeeze Risk
Short Interest?4.6M
Days to Cover?8.2
Free Float17.1M
Avg Daily Volume566.9K
Settlement Date2026-06-15
Financial Health
Current Ratio?7.58Strong
Quick Ratio?7.58Strong
Cash Ratio?5.96Strong
Debt/Equity?0.00Low
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score33/100
P/E?N/A▾
P/B?144.17HIGH▾
Peers100
S&P3
P/S?7.91HIGH▾
Peers100
S&P13
P/FCF?416.8PRICEY▾
Peers100
S&P3
EV/EBITDA?38.4HIGH▾
Peers100
S&P6
EV/Sales?6.84HIGH▾
Peers100
S&P21
Returns & Efficiency
ROE?-210.1%WEAK▾
S&P3
ROA?-8.1%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$4.4M
Enterprise Value?$1.6B
Fundamentals ratios updated end of day